Supna Lowery, MD
Endocrinology, Diabetes & Metabolism · Fairfax, VANPI 1558308502
Payments from drug & device makers
Across 52 payments — averaging $18.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Xeris Pharmaceuticals, Inc.$135
- Novo Nordisk$130
- Lilly USA, LLC$105
- Sanofi-aventis U.S. LLC$78
- Abbott$50
- Amarin Pharma, Inc.$49
- plus $411 from 14 others
What the payments were for
- Food & beverage$90895%
- Education$505%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Xeris Pharmaceuticals, Inc. | 1 | $135 |
| Novo Nordisk | 8 | $130 |
| Lilly USA, LLC | 7 | $105 |
| Sanofi-aventis U.S. LLC | 5 | $78 |
| Abbott | 1 | $50 |
| Amarin Pharma, Inc. | 3 | $49 |
| Boehringer Ingelheim | 3 | $48 |
| AstraZeneca | 3 | $47 |
| IBSA Pharma Inc. | 3 | $46 |
| Johnson & Johnson | 3 | $39 |
| AbbVie | 2 | $39 |
| Merck | 3 | $38 |
| Tandem Diabetes Care, Inc. | 2 | $31 |
| Corcept Therapeutics | 1 | $25 |
| Dexcom, Inc. | 2 | $22 |
| Shire North American Group Inc | 1 | $18 |
| Companion Medical, Inc. | 1 | $17 |
| Valeritas, Inc. | 1 | $16 |
| Insulet Corporation | 1 | $15 |
| Amneal Pharmaceuticals LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KEVEYIS$135
How this compares
$958 in reported general payments places this provider in the 40th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.
See all endocrinology, diabetes & metabolism providers in Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 103 | $203,355 |
| TrulicityDulaglutide | 51 | $123,339 |
| JardianceEmpagliflozin | 93 | $117,996 |
| Tresiba Flextouch U-200Insulin Degludec | 29 | $56,936 |
| JanuviaSitagliptin Phosphate | 39 | $54,298 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $29,143 |
| FarxigaDapagliflozin Propanediol | 16 | $27,918 |
| TradjentaLinagliptin | 21 | $24,863 |
| MounjaroTirzepatide | 15 | $17,931 |
| Humalog Kwikpen U-200Insulin Lispro | 11 | $17,681 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 34 | $17,105 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 100 | $16,029 |
| Humalog Kwikpen U-100Insulin Lispro | 57 | $15,465 |
| SynthroidLevothyroxine Sodium | 109 | $10,457 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 75 | $9,106 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $130 | $203,355103 claims |
| Boehringer IngelheimJardiance, Tradjenta | $48 | $142,859114 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $105 | $141,27066 claims |
| MerckJanuvia | $38 | $54,29839 claims |
| AstraZenecaFarxiga | $47 | $27,91816 claims |
| AbbVieSynthroid | $39 | $10,457109 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $11 | $3,018215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.
Other endocrinology, diabetes & metabolism in Fairfax
- Samim EnayatFairfax$217K
- Denise ArmelliniFairfax$152K
- Yasser OusmanFairfax$53K
- Roy LangleyFairfax$5K
- Domenica RubinoArlington$3M
- Suzanne Jan de BeurCharlottesville$1.5M
- Farhad ZangenehSterling$1.2M
- Ali IranmaneshSalem$1.1M
- Elias SirajNorfolk$884K
- James MulindaRoanoke$788K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.